Improving viral vector safety for gene therapies
Drug Discovery World
AUGUST 21, 2024
Dr Andrea O’Hara, Senior Product Manager at Azenta Life Sciences asks why integration site analysis (ISA) is critical for the safety and efficacy of viral vectors for gene therapy. The composition of engineered cells in vivo can change over time as clones proliferate at varying rates. to 10% in hepatocytes.
59 
Let's personalize your content